2. Search Result
Search Result
Results for "

monocyte migration

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Peptides

1

Inhibitory Antibodies

2

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-110247
    TRAF-STOP inhibitor 6877002
    4 Publications Verification

    		 TNF Receptor NF-κB Cardiovascular Disease Inflammation/Immunology
    TRAF-STOP inhibitor 6877002 is a selective CD40-TRAF6 interaction inhibitor. TRAF-STOP inhibitor 6877002 exerts anti-atherosclerotic activity by blocking the CD40-TRAF6 signaling pathway, inhibiting classical monocyte activation, leukocyte recruitment, and macrophage activation and migration. TRAF-STOP inhibitor 6877002 reduces the phosphorylation levels of signaling intermediates in the canonical NF-κB pathway .
    TRAF-STOP inhibitor 6877002
  • HY-103363
    SB-328437
    3 Publications Verification

    		 CCR Thymidylate Synthase Inflammation/Immunology Cancer
    SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .
    SB-328437
  • HY-130332
    Mitomycin A

    		Macrophage migration inhibitory factor (MIF) Cancer
    Mitomycin A is an antitumor agent. Mitomycin A inhibits the spontaneous migration of mouse monocytes. Mitomycin A inhibits the production of MIF (Migration Inhibition Factor) by human lymphocytes. Mitomycin A can be used in the research of tumor diseases .
    Mitomycin A
  • HY-139481
    TL-895
    1 Publications Verification

    		 Btk BMX Kinase Interleukin Related TNF Receptor Neurological Disease Inflammation/Immunology Cancer
    TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor. TL-895 is active against recombinant BTK (average IC50: 1.5 nM) and inhibits only three additional kinases BLK, BMX (IC50 = 1.6 nM) and TXK with IC50 within tenfold of BTK activity. TL-895 inhibits BTK auto-phosphorylation at the Y223 phosphorylation site (IC50: 1-10 nM). The TL-895 effectively inhibits the production of inflammatory factors such as IL-8, IL-1β, MCP-1 and TNF-α by monocytes or macrophages, and reduces the chemotactic migration of MF cells towards SDF-1. TL-895 is used be for studies of chronic lymphocytic leukemia (CLL), myelofibrosis (MF), and B-cell malignancies .
    TL-895
  • HY-164548
    WK88-1

    		HSP Apoptosis PI3K Akt NF-κB Inflammation/Immunology Cancer
    WK88-1 is an apoptosis inducer and Hsp90 client protein inhibitor with antiproliferative and immunomodulatory activities. WK88-1 inhibits signaling pathways such as PI3K/Akt and NF-κB, and induces mitochondrial dysfunction and cell cycle arrest. WK88-1 effectively suppresses cancer cell migration and invasion, and reverses various EGFR mutations and resistance to Gefitinib (HY-50895). WK88-1 also regulates the differentiation of monocytes and dendritic cells, blocks the expression of multiple chemokines, inhibits immune cell migration and M1 marker transcription, and restores impaired endocytic activity. WK88-1 has been used in studies of breast cancer, non-small cell lung cancer with various EGFR mutations or Met amplification, and atherosclerosis and other related diseases .
    WK88-1
  • HY-16384
    L-156602

    Antibiotic L 156602; PD 124966

    		 Complement System Inflammation/Immunology
    L-156602 is a C5a receptor antagonist. L-156602 inhibits inflammation, and the migration of monocytes and neutrophils to the infiltrating site in mouse inflammatory models. L-156602 suppresses the efferent phase of delayed-type hypersensitivity (DTH) .
    L-156602
  • HY-B1453R
    (±)-Carnitine chloride (Standard)

    DL-Carnitine chloride (Standard); DL-Levocarnitine chloride (Standard)

    		 Reference Standards Reactive Oxygen Species (ROS) Metabolic Disease
    Benoxaprofen (Standard) is the analytical standard of Benoxaprofen. This product is intended for research and analytical applications. Benoxaprofen (LRCL 3794) is a potent and long-acting anti-inflammatory and antipyretic compound. Benoxaprofen is a relatively weak inhibitor of cyclooxygenase in in vitro systems, inhibits lipoxygenase in other systems, and inhibits monocyte migration in some animal models of inflammation .
    (±)-Carnitine chloride (Standard)
  • HY-13568R
    Benoxaprofen (Standard)

    LRCL 3794 (Standard)

    		 Reference Standards COX Cytochrome P450 Lipoxygenase PGE synthase Inflammation/Immunology
    Benoxaprofen (Standard) is the analytical standard of Benoxaprofen. This product is intended for research and analytical applications. Benoxaprofen (LRCL 3794) is a nonsteroidal anti-inflammatory agent that blocks the biosynthesis of inflammatory mediators such as leukotrienes and prostaglandins by inhibiting 5-LOX, PGH2 synthase and cytochrome P-450. Benoxaprofen exhibits significant toxicity: it not only alters cellular redox status, uncouples oxidative phosphorylation and disrupts calcium ion homeostasis, but also causes liver injury through the formation of covalent adducts between its active metabolites and hepatic proteins. Benoxaprofen shows strong phototoxicity under ultraviolet irradiation, and induces erythrocyte lysis, mast cell degranulation and histamine release. Benoxaprofen is widely used in studies of urticaria and related phototoxic mechanisms .
    Benoxaprofen (Standard)
  • HY-159580
    STAT3-IN-31

    		STAT Cancer
    STAT3-IN-31 (compound K2071) is a STATtic-derived STAT3 and mitotic inhibitor. STAT3-IN-31 blocks mitotic progression and affects the formation of mitotic spindles. STAT3-IN-31 also affects glioblastoma cell migration and inhibits cell proliferation in tumor spheroids. STAT3-IN-31 is also able to induce glioblastoma senescence, inhibit the growth of Temozolomide (HY-17364)-resistant cells and the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein MCP-1 .
    STAT3-IN-31
  • HY-P11780
    KAFDITYVRLKF

    		Integrin MMP Neurological Disease Cancer
    KAFDITYVRLKF is a selective, competitive integrin αvβ3 binder. KAFDITYVRLKF induces the production of MMP-9. KAFDITYVRLKF blocks monocyte migration, promotes melanoma cell migration, protects neurons, and improves motor and cognitive functions. KAFDITYVRLKF can be used in research related to melanoma and Parkinson's disease .
    KAFDITYVRLKF
  • HY-180571
    LUF7996

    		PROTACs CCR Cancer
    LUF7996 is a CCR2 PROTAC Degrader degrading CCR2 with DC50 = 2.6 μM. LUF7996 demonstrates engagement of both and the E3 ligase cereblon and displays sustain and concentration-dependent degradation of CCR2. LUF7996 reliance on the lysosomal pathway to induce CCR2 degradation. LUF7996 efficiently inhibits monocyte migration in virto .
    LUF7996
  • HY-P991937
    SOL-116

    		Lipase Inflammation/Immunology
    SOL-116 is a humanized anti-BSSL antibody. SOL-116 blocks BSSL from binding to monocytes. SOL-116 reduces the severity of Pristane (HY-N7819)-induced arthritis in rats .
    SOL-116
  • HY-103363R
    SB-328437 (Standard)

    		Reference Standards CCR Thymidylate Synthase Inflammation/Immunology Cancer
    SB-328437 (Standard) is the analytical standard of SB-328437 (HY-103363). This product is intended for research and analytical applications. SB-328437 is a potent, selective non-peptide CCR3 antagonist with an IC50 of 4.5 nM. SB-328437 can inhibit eosinophil migration induced by eotaxin, eotaxin-2, and monocyte chemotactic protein-4. In addition, SB-328437 can sensitize 5-FU (HY-90006)-resistant gastric cancer cells. SB-328437 can also reduce the recruitment of neutrophils to the lungs and pulmonary inflammation during acute inflammation. SB-328437 can be used in the research of inflammation-related diseases .
    SB-328437 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: